GlassScriptPhysician profile
Long Qin Wang
NPI 1235661349
$1,588.31
in general payments reported to CMS, 2019-2025
19 companies · $636 in 2025
The $636 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $110 · 2024: $842 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $269.73 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $213.03 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $193.37 | 2024-2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $190.32 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $167.02 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $111.43 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $84.75 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $71.67 | 2023-2025 | |
| Amgen INC. | $59.11 | 2024-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $55.93 | 2025 | Veozah |
| Dexcom, INC. | $34.62 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.36 | 2025 | Korlym |
| Abbvie INC. | $19.72 | 2023 | Ubrelvy |
| Cagent Vascular INC | $19.00 | 2025 | Serrantor |
| Lundbeck LLC | $18.45 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $15.60 | 2023 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $15.14 | 2024 | Horizant |
| Currax Pharmaceuticals LLC | $14.71 | 2025 | Contrave |
| Phathom Pharmaceuticals, INC. | $14.35 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.